About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
OMER - Omeros Corporation| Previous Close | $18.06 | Open | $19.44 |
| Volume | 2.24M | Market Cap | 904.14M |
| Yield | Last Dividend |
| Biologics License Application for Narsop... | 8:30 AM |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treat... | |
| Omeros to Present at the 39th Annual J.P... | 01/11/21 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, wil... | |
| CMS Confirms Continued Separate Payment ... | 12/03/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate... | |
| Omeros Submits its Biologics License App... | 11/18/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Applicatio... | |
| Obsessive Compulsive Disorder (OCD) Mark... | 11/18/20 |
| All information provided in the report is derived from trusted industrial sources. Global Obsessive Compulsive Disorder (OCD) Market research reports ... | |
| Global Nicotine Addiction Treatment Mark... | 11/12/20 |
| This Nicotine Addiction Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and t... | |
| Omeros Corporation Reports Third Quarter... | 11/09/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and com... | |
| Omeros Earnings and Growth Analysis : St... | 11/09/20 |
| Omeros announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Omeros Corporation to Announce Third Qua... | 11/05/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the pe... | |
| Opioid Use Disorder Market Trends Estima... | 11/03/20 |
| Opioid Use Disorder (OUD) is a type of chronic disorder that is associated with repeated self-administration of opioids, prolonged self-administration... | |
| Omeros Participates in Investor Conferen... | 10/28/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19... | |
| Global Opioid Use Disorder Market (Covid... | 10/22/20 |
| Data Bridge Market Research has recently added a concise research on the Global Opioid Use Disorder Market- Industry Trends and Forecast to 2026. A re... | |
| Omeros (NASDAQ:OMER) Earns Buy Rating fr... | 10/20/20 |
| Analysts at Bank of America started coverage on shares of Omeros (NASDAQ:OMER) in a report issued on Tuesday, The Fly reports. The firm set a ???buy??... | |
| Omeros??? OMS906 Data Presented at Compl... | 10/16/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Developm... | |
| Omeros Schedules Webcast to Present Fina... | 10/15/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatmen... | |
| Omeros Provides Update on Separate Payme... | 10/01/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMID... | |
| Omeros to Present at the Cantor Virtual ... | 09/11/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, wil... | |
| Omeros??? Investigational New Drug Appli... | 08/31/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 ... | |
| The Daily Biotech Pulse: Regulatory Setb... | 08/11/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Techno... | |
| Omeros EPS misses by $0.02, misses on re... | 08/10/20 |
| Omeros (NASDAQ:OMER): Q2 GAAP EPS of -$0.61 misses by $0.02. Revenue of $13.53M (-49.4% Y/Y) misses by $3.57M. Press Release | |
| Omeros Announces Proposed Public Offerin... | 08/10/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (???Omeros???) today announced that it has commenced concurrent underwritten public offeri... | |
| Omeros Corporation Reports Second Quarte... | 08/10/20 |
| Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecul | |
| Omeros Rallies On COVID-19 Study Results... | 08/10/20 |
| Omeros Corporation (NASDAQ: OMER ) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lea... | |
| Drug developer Omeros reports positive r... | 08/10/20 |
| Omeros said all six patients, who needed mechanical ventilation before treatment, recovered and were discharged from hospital | |
| Omeros : reports full recovery from seve... | 08/10/20 |
| Omeros Corp on Monday reported positive results from a six-patient study of its investigational treatment for Acute Respiratory Distress Syndrome caus... | |
| Omeros Corporation Reports Recovery and ... | 08/10/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros??? ... | |
| Omeros??? Narsoplimab Pivotal Trial Data... | 06/12/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of h... | |
| Omeros??? Narsoplimab Pivotal Trial Data... | 06/11/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER): The results of Omeros??? pivotal trial of narsoplimab for the treatment of hematopoietic ... | |
| Omeros Corporation Announces Presentatio... | 05/14/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of h... | |
| Should You Buy Omeros (OMER) Ahead of Ea... | 05/08/20 |
| Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | |
| Buy rating | 01/04/21 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $32.00 to $31.00 | |
| Date | 2020-11-09 (AMC) | Est. (EPS/Rev.) | ($0.61)/ 19.11M |
| Actual (EPS/Rev.) | $-0.43/ $26.11 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Bye Bye Patron | Bye bye patron | 83.00 % | Follow |
| Tech Trades | Tech Trades | 81.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Burdeshaw Investing | Matthew Burdeshaw | 55.00 % | Subscribe |
| Biotech picks | mr jackson | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
